不同剂量乌司他丁联合微量推注泵美罗培南对重症肺炎患者的疗效 及血管生成素2 的影响.

Objective: To explore and analyze the curative effect of different doses of ulinastatin combined with micro injection pump meropenem on patients with severe pneumonia and the influence of angiopoietin-2. Methods: From January 2019 to February 2022, 78 patients with severe pneumonia who were diagnosed and treated in our hospital were selected as research objects, and they were divided into a research group and a control group with 39 cases in each group. Both groups were given micro-bolus injection of meropenem. The study group and the control group were treated with high-dose and low-dose ulinastatin, respectively, for 7 consecutive days, and the curative effect and serum angiopoietin-2 expression changes were observed. Results: The ICU hospitalization time, antipyretic time, inflammation absorption time and sputum color change time of the study group were shorter than those of the control group (P<0.05). The total effective rate of the treatment group was higher than that of the control group (P<0.05). The levels of serum interleukin-6 (IL-6) and interleukin-17 (IL-17) in the two groups after treatment were significantly lower than those before treatment (P<0.05). The -17 content was also significantly lower than that in the control group (P<0.05). The serum Angiopoietin-2 content of the two groups after treatment was lower than that before treatment, and the serum Angiopoietin-2 content of the study group was lower than that of the control group after treatment (P<0.05). Conclusion: The application of high-dose ulinastatin combined with micro-injection pump meropenem in patients with severe pneumonia can inhibit the expression of serum angiopoietin-2, as well as the expression of serum IL-6 and IL-17, thereby improving the therapeutic effect. The effect is to promote the improvement of the patient's clinical symptoms, which is conducive to the recovery of the patient. [ABSTRACT FROM AUTHOR]